Patents by Inventor Kenneth C. Anderson

Kenneth C. Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9950047
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: April 24, 2018
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Publication number: 20170356917
    Abstract: The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.
    Type: Application
    Filed: October 20, 2015
    Publication date: December 14, 2017
    Inventors: Teru Hideshima, Kenneth C. Anderson, Francesca Cottini
  • Patent number: 9770497
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: September 26, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Patent number: 9572854
    Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: February 21, 2017
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
  • Publication number: 20160272579
    Abstract: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 22, 2016
    Inventors: Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Stephen J. Haggarty, Balaram Ghosh
  • Publication number: 20160137735
    Abstract: Compositions and methods for treating MM are provided herein.
    Type: Application
    Filed: August 24, 2015
    Publication date: May 19, 2016
    Inventors: Daniel AFAR, Kenneth C. Anderson, Yu-Tzu Tai
  • Patent number: 9309564
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: April 12, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., Board of Trustees of the University of Arkansas
    Inventors: Ronald A. DePinho, Kenneth C. Anderson, Ruben D. Carrasco, Giovanni Tonon, Cameron Brennan, John D. Shaughnessy, Jr., Lynda Chin
  • Publication number: 20160051619
    Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
    Type: Application
    Filed: April 6, 2015
    Publication date: February 25, 2016
    Applicants: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
  • Patent number: 9248124
    Abstract: The present invention provides inhibitors of I?B kinase of general formula (I). or a stereoisomer or physiologically tolerable salt thereof, for use in the inhibition of the growth of a multiple myeloma cell and for use in the treatment of multiple myeloma, wherein R1-R8 and B6-B9 are described in the specification.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: February 2, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Kenneth C. Anderson
  • Publication number: 20160008444
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: June 29, 2015
    Publication date: January 14, 2016
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Publication number: 20150297695
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: November 5, 2013
    Publication date: October 22, 2015
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Patent number: 9096681
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: August 4, 2015
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Publication number: 20150191417
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound of the invention may enhance the anti-tumor immune response by inhibiting or eliminating the immune suppression mediated by immune suppressor myeloid cells (MDSCs), inducing apoptosis, and/or inhibit or down-regulate proteins (e.g., epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), X-linked inhibitor of apoptosis protein (XIAP), and heat shock protein 90 (Hsp90)) in the subject.
    Type: Application
    Filed: July 10, 2013
    Publication date: July 9, 2015
    Applicants: Dana-farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kenneth C. Anderson, Teru Hideshima, Ralph Mazitschek, Gullu Gorgun
  • Publication number: 20150105358
    Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 16, 2015
    Applicant: Acetylon Pharmaceuticals, Inc.
    Inventors: Steven Norman Quayle, Simon Stewart Jones, Kenneth C. Anderson, Teru Hideshima
  • Patent number: 8999289
    Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: April 7, 2015
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
  • Publication number: 20140349965
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Application
    Filed: March 25, 2014
    Publication date: November 27, 2014
    Applicants: Dana-Farber Cancer Institute, Inc., Triphase Research and Development I Corp.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Publication number: 20140322201
    Abstract: Compositions and methods for treating MM are provided herein.
    Type: Application
    Filed: December 23, 2013
    Publication date: October 30, 2014
    Inventors: Daniel Afar, Kenneth C. Anderson, Yu-Tzu Tai
  • Patent number: 8722724
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: May 13, 2014
    Assignees: Triphase Research and Development I Corp., Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Patent number: 8685954
    Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: April 1, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
  • Patent number: 8632772
    Abstract: Compositions and methods for treating MM are provided herein.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: January 21, 2014
    Assignee: Dana-Farber Cancer Institute
    Inventors: Kenneth C. Anderson, Yu-Tzu Tai